Healthcare

Orthocell Ltd (ASX:OCC), the Australian regenerative medicine company, has placed its shares into a trading halt as it awaits a pivotal decision from the U.S. Food and Drug Administration (FDA) regarding regulatory clearance for its flagship Remplir nerve repair product.

Shares of Australian medical gear maker Ansell Ltd (ASX:ANN) rose 4.02% during afternoon trade on Friday, recovering some ground after a sharp selloff in the previous session saw the stock plunge as much as 16.4%. The rebound followed the company’s assurance that it will …

Shares of New Zealand-based Fisher & Paykel Healthcare (FPH) surged as much as 2.9%, reaching NZ$35.43, their highest point since 21 February 2025. This jump follows an upgrade by analysts at Jefferies, who raised their rating for the medical equipment maker from "hold" to …

Pro Medicus Ltd (ASX:PME) has announced a 10.2 million share buyback, set to take place between 1 April 2025 and 31 March 2026. This move comes as the once high-flying healthcare technology stock has fallen sharply, currently trading at $198 per share, a 33% …

Mesoblast (ASX: MSB, Nasdaq: MESO), a leader in allogeneic cellular medicines, has announced that it has entered into a Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS). This agreement enables the U.S. government to provide access …

Australian drug development company Nyrada Inc. (ASX:NYR) has made significant progress in its clinical research, dosing its first group of patients in a Phase I trial for its lead drug candidate, NYR-BI03. The experimental treatment aims to reduce long-term disabilities associated with stroke and …

Australian healthcare services company Healius (ASX:HLS) has announced an ambitious EBIT margin target for FY27, aiming for a high single-digit percentage. This projection exceeds analyst expectations from both Citi and Jefferies, sparking mixed reactions from the market.